Polyclinique de Courlancy
- Address
- Rue Louis-Victor de Broglie, 51430 Bezannes, France
Polyclinique de Courlancy - Dermatological Research Center
Polyclinique de Courlancy is a clinical research facility specializing in advanced dermatological conditions and innovative therapeutic interventions. The center demonstrates particular expertise in complex inflammatory skin disorders, contributing to pivotal international studies that evaluate novel treatment modalities for chronic and debilitating dermatological diseases.
- Hidradenitis Suppurativa treatment research and clinical trials
- Evaluation of targeted immunomodulatory therapies for inflammatory skin conditions
- Safety and efficacy assessment of novel pharmaceutical agents in dermatology
The center's research portfolio focuses on conditions that significantly impact patient quality of life, with active participation in Phase II and III trials examining povorcitinib and other emerging therapies. Through rigorous evaluation of moderate to severe hidradenitis suppurativa treatments, Polyclinique de Courlancy contributes valuable clinical data to advance understanding of chronic inflammatory skin disorders and expand therapeutic options for patients with limited treatment alternatives.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Polyclinique de Courlancy
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa: A Phase 3, Randomized, Placebo-Controlled Study | Incyte Corp. | Phase III | Not Recruiting | Jun 2023 | Nov 2025 |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide | 1 | Unknown | 2023-06-02 | 2023-06-02 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.